 Glycopeptide antibiotics such as vancomycin and tycoplanin have been widely used as drugs of last resort against gram-positive pathogens such as methicillin-resistant Staphylococcus aureus, MRSA. However, increasing levels of resistance to these drugs are being observed, making it necessary to explore alternative approaches to combat this problem. Nanoparticles offer a potential solution by providing a platform for delivering existing antibiotics in a more effective manner. This paper reviews recent advances in the field of biomedical nanotechnology, focusing on the development of nanoparticle-based formulations of glycopeptides. These formulations can potentially restore the efficacy of glycopeptides against MRSA strains that have developed resistance to the original drugs. This article was authored by Banu Kiran-Pathanini and Adrienne Keller.